trazodone-sleep-cognition-ad-nct05282550

Trazodone for Sleep and Cognition in Early Alzheimer's Disease

Overview

Trazodone for Sleep and Cognition in Early Alzheimer's Disease

Overview

NCT05282550 is a Phase 2 clinical trial conducted at Johns Hopkins University evaluating the use of trazodone for improving sleep quality and cognitive function in patients with early Alzheimer's disease (AD). This trial addresses a critical unmet need: sleep disturbances are extremely common in AD, affecting 40-50% of patients, and are both a consequence and contributor to disease progression["@nct05282550"].

The trial is particularly significant because it investigates an existing, well-established medication for a novel indication in neurodegeneration. Trazodone is already widely prescribed for insomnia in the general population, and this trial seeks to determine whether it can provide similar benefits in the AD population while potentially modulating disease-relevant pathological processes.

Background

Sleep Disturbances in Alzheimer's Disease

Sleep disturbances in AD represent a bidirectional relationship with disease pathology, where each exacerbates the other in a vicious cycle:

Prevalence and Impact

• 40-50% of AD patients experience significant sleep disturbances
• Sleep problems often appear before cognitive symptoms
• Disturbances worsen as disease progresses
• Associated with increased behavioral symptoms
• Significantly impacts caregiver well-being

| Type | Description | Prevalence in AD |
|------|-------------|-----------------|
| Insomnia | Difficulty initiating/maintaining sleep | 40-60% |
| Sleep fragmentation | Frequent nighttime awakenings | 50-70% |
| Circadian rhythm changes | Advanced sleep phase, irregular patterns | 30-50% |
| Excessive daytime sleepiness | Daytime naps, reduced alertness | 25-40% |
| REM sleep behavior | Loss of muscle atonia during REM | 20-30% |

Bidirectional Relationship: Sleep and AD Pathology

The relationship between sleep and AD is bidirectional, creating a self-perpetuating cycle:

Sleep Disruption Accelerates AD Pathology

• Glymphatic system clearance is sleep-dependent
• Amyloid-β accumulation increases with sleep disruption
• Tau pathology spreads during sleep
• Sleep deprivation impairs synaptic homeostasis
• Inflammation increases with poor sleep[@WU2022]

• Amyloid deposition in sleep-wake centers
• Tau pathology in hypothalamic nuclei
• Neurotransmitter system dysfunction
• Circadian rhythm generator damage
• Sleep architecture abnormalities

Current Treatment Landscape

Current options for sleep disturbances in AD are limited:

Pharmacological Approaches

• Benzodiazepines: Effective but significant risks in elderly
• Z-drugs (zolpidem, eszopiclone): Risks include falls, confusion
• Antipsychotics: Reserved for severe agitation, significant risks
• Antihistamines: Cognitive side effects, anticholinergic risk
• Melatonin: Limited efficacy data in AD

• Sleep hygiene education
• Light therapy
• Cognitive behavioral therapy for insomnia (CBT-I)
• Regular exercise
• Environmental modifications

• Well-established safety profile
• Non-benzodiazepine mechanism
• Low anticholinergic burden
• Dual sleep promotion and potential neuroprotective effects
• Extensive clinical experience in older adults[@sherman2015]

Trazodone: Pharmacology and Mechanisms

Basic Pharmacology

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) with complex pharmacology:

Classification

• Chemical class: Triazolopyridine derivative
• Primary mechanism: 5-HT2A antagonist, 5-HT1A partial agonist
• Secondary effects: α1-adrenergic blockade, histamine H1 blockade
• Metabolite: mCPP (meta-chlorophenylpiperazine)

• Oral bioavailability: High (>90%)
• Peak plasma time: 1-2 hours
• Half-life: 5-9 hours (extended in elderly)
• Metabolism: hepatic (CYP3A4)
• Excretion: renal

Sleep-Promoting Mechanisms

Trazodone promotes sleep through multiple mechanisms:

1. 5-HT2A Receptor Antagonism

• Blocks serotonergic excitation
• Promotes sleep continuity
• Reduces sleep fragmentation
• Minimal next-day sedation

• Modulates sleep architecture
• May enhance deep sleep
• anxiolytic effects support sleep

• Reduces arousal
• Promotes sedation
• May contribute to hypotension risk

• Sedative effects
• Counteracts daytime alertness

• Complex effects on sleep
• May contribute to sleep architecture

Potential Neuroprotective Effects

Beyond sleep promotion, trazodone may have disease-relevant effects:

Serotonergic Neuroprotection

• 5-HT2A modulation may affect amyloid processing
• Serotonergic system preservation in AD
• Anti-inflammatory effects via serotonin pathways

• 5-HT2C modulation may influence cognition
• Potential effects on neurogenesis
• Unknown significance in AD

• Improved sleep → enhanced glymphatic clearance
• Reduced behavioral symptoms
• Better caregiver sleep and well-being
• Potential slowdowns in disease progression

Trial Design and Methods

Study Overview

The NCT05282550 trial employs a rigorous design:

| Parameter | Value |
|-----------|-------|
| Phase | Phase 2 |
| Design | Randomized, double-blind, placebo-controlled |
| Duration | 24 weeks |
| Sample Size | ~100 participants |
| Sponsor | Johns Hopkins University |
| Lead Investigator | Dr. Adam P. Spira |

Patient Population

Inclusion Criteria

• Age 60-85 years
• Diagnosis of early AD (MCI due to AD or mild AD dementia)
• Clinically significant sleep disturbance (ISI score >7)
• Stable cholinesterase inhibitor or memantine use (if applicable)
• Reliable caregiver available
• Able to undergo polysomnography

• Severe depression (MADRS > 20)
• Uncontrolled sleep disorders (obstructive sleep apnea, restless legs syndrome)
• Use of other sedating medications
• Significant cardiovascular disease
• Prior trazodone use for sleep
• Severe medical conditions

Treatment Arms

| Arm | Treatment | Dose | Schedule |
|-----|-----------|------|----------|
| Active | Trazodone | 25-150 mg (flexible) | Nightly, as needed |
| Placebo | Matching placebo | Same regimen | Nightly, as needed |

Dosing Strategy

• Low starting dose: 25 mg
• Flexible titration up to 150 mg based on response
• As-needed use (not nightly required)
• Allows for individual optimization
• Minimizes unnecessary exposure

Outcome Measures

Primary Endpoints

• Primary objective measure
• Percentage of time in bed spent sleeping
• Direct measure of sleep quality

• Primary clinical endpoint
• Comprehensive cognitive assessment
• Sensitive to early AD changes

• Sleep quality (PSQI - Pittsburgh Sleep Quality Index)
• Neuropsychiatric symptoms (NPI)
• Actigraphy measures (home sleep monitoring)
• Caregiver burden
• CSF biomarkers (optional sub-study)
• Brain imaging (optional sub-study)

• Nighttime sleep architecture (REM, NREM stages)
• Daytime alertness
• Inflammatory markers

Study Visits

| Visit | Timing | Assessments |
|-------|--------|--------------|
| Screening | -4 weeks | Medical history, physical, cognitive testing |
| Baseline | Day 0 | PSG setup, cognitive testing, labs |
| Visit 2 | Week 4 | Safety, sleep diary, titration review |
| Visit 3 | Week 12 | Primary efficacy assessments |
| Visit 4 | Week 24 | Final assessments, PSG |

Statistical Analysis

Sample Size Calculation

• Power: 80%
• Alpha: 0.05 (two-sided)
• Expected effect size: 0.5 (medium)
• Anticipated dropout: 15%

• Mixed-effects model for repeated measures
• Intention-to-treat population
• Per-protocol sensitivity analysis

Rationale and Hypothesis

Why Treat Sleep in Early AD?

The trial is based on several key premises:

1. Sleep Disturbances Are Modifiable

• Unlike amyloid and tau pathology, sleep can be directly improved
• Existing effective treatments for sleep in general population
• Even partial improvement may have meaningful impact

• Early AD may have more reserve to benefit
• Sleep improvements may slow downstream pathology
• Earlier treatment may prevent cascade of complications

• Improving sleep may reduce pathology accumulation
• Reducing pathology may improve sleep
• Potential synergistic benefits over time

Hypothesis

The trial tests the primary hypothesis that:
> Trazodone will improve sleep efficiency and slow cognitive decline in patients with early AD compared to placebo.

Secondary Hypotheses

• Sleep improvement will correlate with reduced AD biomarker changes
• Benefits will be maintained throughout the 24-week treatment period
• Caregiver burden will be reduced with improved patient sleep

Clinical Significance

If successful, this trial would:

Expected Outcomes

Based on Prior Research

Previous research suggests the following outcomes are plausible[@blom2021][@shapira2024]:

Sleep Outcomes

• Sleep efficiency improvement: 5-10% over baseline
• Reduced nighttime awakenings: 20-30% reduction
• Improved sleep continuity
• Enhanced daytime alertness

• Stabilization of cognitive decline (slower progression)
• Potential small improvements in attention and executive function
• Possible benefits in memory consolidation

• Reduced behavioral symptoms
• Improved quality of life
• Decreased caregiver burden

Risk-Benefit Profile

Trazodone offers an attractive risk-benefit profile:

Potential Benefits

• Established efficacy for insomnia
• Well-characterized safety in elderly
• Low anticholinergic burden (important in AD)
• Affordable and accessible

• Orthostatic hypotension (monitor in elderly)
• Next-day sedation (dose-dependent)
• Rare priapism (relevant for patient counseling)
• Serotonin syndrome (rare with monotherapy)
• Cardiac conduction effects (uncommon)

• Low starting dose
• Flexible titration
• Careful monitoring
• Patient/caregiver education

Comparison to Other Studies

Prior Trazodone Research in AD

Several smaller studies have investigated trazodone in AD:

| Study | N | Duration | Key Findings |
|-------|---|----------|---------------|
| Le Bon (2007) | 14 | 4 weeks | Improved sleep, no cognitive worsening |
| Shaw (2012) | 25 | 8 weeks | Improved sleep efficiency |
| Shapira (2024) | 45 | 12 weeks | Improved sleep architecture |
| NCT05282550 | ~100 | 24 weeks | Largest, longest trial |

Unique Contributions of This Trial

The NCT05282550 trial extends prior work:

Implications for AD Treatment

If Positive

A positive result would:

• Establish trazodone as standard of care for sleep in early AD
• Suggest disease-modifying potential through sleep improvement
• Support investigation of other sleep-targeted therapies
• Inform combination approaches (sleep therapy + disease-modifying drugs)

If Negative

A negative result would:

• Require examination of methodology (dose, duration, population)
• Prompt investigation of alternative sleep treatments
• Suggest that sleep improvement alone may be insufficient
• Not diminish importance of sleep management for quality of life

Safety Profile in Elderly

Trazodone Safety in Older Adults

Trazodone has been extensively studied in elderly populations:

Common Side Effects (10-30%)

• Drowsiness (usually diminishes with time)
• Headache
• Dizziness
• Dry mouth

• Orthostatic hypotension
• Gastrointestinal upset
• Blurred vision
• Urinary retention

• Serotonin syndrome (with other serotonergic drugs)
• Cardiac arrhythmias (preexisting heart disease)
• Priapism (0.1%)

Considerations in AD Population

Special considerations for AD patients:

Future Directions

Combination Approaches

If successful, trazodone could be combined with:

• Anti-amyloid antibodies (lecanemab, donanemab)
• Tau-directed therapies
• Neuroprotective agents

• Cholinesterase inhibitors
• Memantine

• CBT-I
• Light therapy
• Exercise programs

Precision Medicine Approaches

Future research could identify:

• Sleep phenotype subtypes responsive to treatment
• Genetic predictors of response
• Biomarkers for patient selection
• Optimal treatment duration

Cross-References

• [Alzheimer's Disease](/diseases/alzheimers-disease) — Disease page
• [Sleep Disorders in Neurodegeneration](/mechanisms/sleep-disorders-neurodegeneration) — Mechanism
• [Clinical Trials Dashboard](/clinical-trials/dashboard) — Hub page
• [Other AD Clinical Trials](/clinical-trials/alzheimers-disease) — Related trials
• [Amyloid-Tau-Neurodegeneration Framework](/mechanisms/atn-framework) — Disease model

Summary

The NCT05282550 trial represents a pragmatic, evidence-based approach to addressing sleep disturbances in early Alzheimer's disease. By repurposing an existing medication with a favorable safety profile, this trial could establish a new standard of care that simultaneously improves quality of life and potentially modifies disease progression.

Key Points

The trial addresses a critical unmet need while exploring a novel disease-modifying mechanism through sleep improvement, representing a promising approach to AD treatment.

References